Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Confronting proviral HIV infection.

David M Margolis1

  • 1Department of Medicine, 3302 Michael Hooker Research Building, CB#7435, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7435, USA. dmargo@med.unc.edu

Current HIV/AIDS Reports
|June 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell analysis of HIV expression and integration sites reveals robust viral expression across diverse chromatin environments.

Microbiology spectrum·2026
Same author

A screen of chromatin-targeting compounds identifies TAF1 as a novel regulator of HIV latency.

mBio·2026
Same author

MVA.HIVconsvX vaccination-evoked T cell expansion inversely associates with age in people with HIV-1 on antiretroviral therapy.

The Journal of clinical investigation·2026
Same author

The ENL-USP7 Complex Regulates HIV Latency Through BRD4 Stabilization.

bioRxiv : the preprint server for biology·2026
Same author

Histone decrotonylation plays a distinct role in HIV latency.

Science advances·2026
Same author

Single cell multiomic analysis of the impact of Delta-9-tetrahydrocannabinol on HIV infected CD4 T cells.

Journal of cannabis research·2026
Same journal

IAS 2025: Why Can't I Breastfeed My Baby When Evidence and Lived Experience Say I Can? A Call for Policy Equity for Mothers Living with HIV.

Current HIV/AIDS reports·2026
Same journal

Cytomegalovirus and HIV Co-Infections During Pregnancy and Early Childhood.

Current HIV/AIDS reports·2026
Same journal

HIV Reservoirs in Brain parenchyma and Cerebrospinal Fluid During Suppressive ART: Same-Same or Very Different?

Current HIV/AIDS reports·2026
Same journal

HIV-1 Tat-driven Glutamate Dysregulation: Implications for Cognitive Impairment in HAND.

Current HIV/AIDS reports·2026
Same journal

Central Nervous System HIV Persistence and Clinical Consequences During Suppressive ART.

Current HIV/AIDS reports·2026
Same journal

Expanding PrEP Access Through Decentralized Delivery Models.

Current HIV/AIDS reports·2026
See all related articles

Antiretroviral therapy (ART) halts HIV infection but doesn't eradicate it. New strategies are needed to eliminate persistent HIV reservoirs, potentially through targeted therapies, to achieve a functional cure for HIV.

Area of Science:

  • Virology
  • Immunology
  • Molecular Biology

Background:

  • Antiretroviral therapy (ART) effectively controls Human Immunodeficiency Virus (HIV) infection by suppressing viral replication.
  • However, ART does not eliminate the latent HIV reservoir, necessitating lifelong treatment and risking viral rebound upon interruption.
  • Eradicating persistent proviral HIV genomes is crucial for achieving a cure.

Purpose of the Study:

  • To explore strategies for depleting the latent HIV reservoir.
  • To identify novel therapeutic targets for HIV eradication beyond current ART limitations.
  • To understand the mechanisms hindering proviral expression and persistence.

Main Methods:

  • Review of current ART limitations and challenges in HIV eradication.

Related Experiment Videos

  • Analysis of factors influencing proviral HIV expression and persistence.
  • Evaluation of emerging therapeutic approaches, including histone deacetylase inhibitors.

    • Main Results:

    • Persistent HIV proviral genomes are maintained by a complex interplay of factors inhibiting expression and virion production.
    • Global T-cell activation strategies combined with ART have not led to HIV eradication.
    • Inhibition of histone deacetylase, a chromatin remodeling enzyme, shows promise and is in clinical trials.

    Conclusions:

    • Achieving HIV eradication requires novel therapeutic strategies that can overcome the barriers to proviral expression.
    • Targeted approaches to eliminate cells harboring latent HIV are necessary.
    • Future therapies may need to focus on selectively inducing expression and eliminating these cells to achieve a functional cure for HIV infection.